News
June 18, 2019

Regenstrief scientist explains how class of drugs may be related to dementia

Regenstrief research scientist Noll Campbell, PharmD, M.S., spoke about a common class of drugs and how it affects the brain on an Indianapolis radio show.

Dr. Campbell was a guest on Caregiver Crossing, which airs every Saturday on 93.1 WIBC. Dr. Campbell addressed the topic of anticholinergics and their potential link to Alzheimer’s and dementia. Anticholinergics are a common class of drug that includes some allergy medications, sleeping pills and many more common medicines.

Dr. Campbell recently received a $3.3 million grant from the National Institute on Aging to conduct the first clinical trial designed to determine if stopping these medications results in sustained improvements in cognition.

Listen to his discussion with the Caregiver Crossing hosts and his advice for people who are taking these medications.

Segment 1

Segment 2

Click here for more information on Caregiver Crossing.

  • Noll Campbell, PharmD, MS

Related News

infographic with statistics from press release

COVID vaccine reduces severity of illness, death for adults, especially among at-risk populations

CDC partnership study includes data from 8 states, 362 E.D.s and urgent care centers, 230 hospitals A new multi-state

Thomas Imperiale

Rectal location and postcolonoscopy colorectal cancer outcomes

Published in the JAMA Network Open. Here is a link to the article. Regenstrief Institute authors: Thomas Imperiale, M.D. This

Arthur Owora, PhD, MPH, and Malaz Boustani, M.D., MPH

New digital marker could improve childhood asthma detection

Researchers at the Indiana University School of Medicine and Regenstrief Institute have developed a more accurate and cost-effective method

Kosali Simon, PhD

Health care workforce recovery after the end of the COVID-19 emergency

The COVID-19 pandemic significantly disrupted health care employment, with effects that varied across subsectors. Initial impacts included a 6.9